EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment

Abstract

The main aim of health technology assessment (HTA) is to inform decision making by health care policy makers. It is a systematic process that evaluates the use of health technologies and generally involves a critical review of international evidence related to clinical effectiveness of the health technology vs. the best standard of care. It can also include an evaluation of cost effectiveness, and social and ethical impacts in the local health care system. The HTA process advises whether or not a health technology should be used, and if so, how it is best used and which patients are most likely to benefit from it. The importance of patient involvement in HTA is becoming widely recognized, for scientific and democratic reasons. The extent of patient involvement in HTA varies considerably across Europe. Commonly HTA is still focused on quantitative evidence to determine clinical and/or cost effectiveness, but the interest in understanding patients' experiences and preferences is increasing. Some HTA bodies provide support for participation in their processes, but again this varies widely across Europe. The involvement of patients in HTA is determined at the national and regional level, and is not subject to any European-wide legislation. The guidance text presented in this article was developed as part of the work of the European Patients' Academy on Therapeutic Innovation (EUPATI) and covers the interaction between HTA bodies and patients and their representatives when medicines are being assessed. Other EUPATI guidance documents relate to patient involvement in pharmaceutical industry-led research and development, ethics committees, and regulatory authorities. The guidance provides recommendations for activities to support patient involvement in HTA bodies and specific guidance for individual HTA processes. It seeks to improve patient involvement, using the outcomes of published research and consensus-building exercises. It also draws on good practice examples from individual HTA bodies. The guidance is not intended to be prescriptive and should be used according to specific circumstances, national legislation, or the unique needs of each interaction. This article represents the formal publication of the HTA guidance text with discussion about recent progress in, and continuing barriers to, patient involvement in HTA.

Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey

“…This includes measuring the burden of disease by use of patient reported outcome tools such as health-related quality of life (HRQoL), the impact of illness on work productivity and the associated economic burden [1]. The evaluation of how migraine affects patients' lives from their perspective is useful for identifying therapeutic areas of need and providing guidance for development of future treatment [2,3].…”

The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview

“…Patients should have direct involvement in coverage decision-making and in the development of the coverage criteria [26, 30]. The European Patients’ Academy (EUPATI) recently released guidance that emphasizes the importance of including patient experience data in Health Technology Assessment (HTA) and summarizing how it was used in reaching the final recommendation [36]. In addition to coverage decision-making, patient experience data may educate healthcare providers on the range of the patient population that benefits from a treatment.…”

Moving forward from drug-centred to patient-centred research

“…These types of questions are crucial not only for patients, but also for HTA bodies and payers [18]. Hence, the importance of the involvement of patients, as partners in the research team and in HTA-related procedures [19]. • Long-term toxicity monitoring of mechanism-based therapies needs to extend beyond registration into real life for a prolonged period.…”